Answers are grounded in this paper and cite their sources.
We examined the prevalence of continuous glucose monitoring (CGM) utilization among eligible Veterans between March 1, 2019, and September 1, 2022, using the Veterans Affairs (VA) Corporate Data Warehouse (CDW). Bivariate analyses examined CGM utilization by Veteran characteristics; survival analyses examined the time elapsed from CGM eligibility to device receipt. The study cohort was 385,222 Veterans, of whom 20,512 (5%) were identified as starting CGM upon eligibility; compared with 364,710 (95%) who did not use CGM despite eligibility within the study period. Continuous glucose monitoring Veterans were more likely to be younger in age (X=67 vs. 71 years; p<.0001; female (p < .0001); White, non-Hispanic (p = .001); and residing in an urban location (p < .0001). Black, non-Hispanic (aHR: 0.81; 95% CI 0.78–0.84) and Hispanic (aHR: 0.76; 95% CI 0.72–0.80) Veterans had a longer delay to CGM use, if it was used at all, compared with their non-Hispanic White counterparts.
No takes yet. Share an insight, caveat, or question.
Kinney et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: